SCHOTT to Produce More Pharmaceutical Glass

Global Pharmaceutical Industry Shows Higher Demand for Type I Glass / New FIOLAX® Tank to Commence Operation in Spring 2016   In response to growing global demand, the SCHOTT Group is expanding its production capacity for pharmaceutical glass.

The company plans to put a new melting tank for its Type I glass named FIOLAX® clear into operation at its site in Mitterteich, Germany. From 2015 to 2016, SCHOTT will be investing a sum in the mid-double-digit millions in the expansion. This move will increase the company’s production capacity for glass tubing to more than 140,000 tons.

FIOLAX® glass tubing is used to manufacture high-quality vials, syringes, ampoules and cartridges. The pharmaceutical industry then fills these with injectable drugs. The needs of the pharmaceutical companies for such high-quality packaging are rising steadily because of an ever-increasing regulatory pressure and more stringent standards for patient safety. FIOLAX® is designed to meet these exact requirements. Thanks to its special properties and its chemical resistance the drugs are kept stored in the best possible way. Since it was first developed more than 100 years ago, FIOLAX® has grown to become the de-facto standard for glass packaging in the pharmaceutical industry.

Construction work on the new tank has already begun and will be completed in spring 2016. Moreover, a new palletizing line will complement the extension.

FIOLAX® is a registered trademark of SCHOTT AG.

Download Link:

SCHOTT is a leading international technology group in the areas of specialty glass and glass-ceramics. The company has more than 130 years of outstanding development, materials and technology expertise and offers a broad portfolio of high-quality products. SCHOTT is an innovative enabler for many industries, including the home appliance, pharmaceutical, electronics, optics, automotive and aviation industries. SCHOTT strives to play an important part of everyone’s life and is committed to innovation and sustainable success. The group maintains a global presence with production sites and sales offices in 35 countries. With its workforce of approximately 15,400 employees, sales of 1.87 billion euros were generated in fiscal year 2013/2014. The parent company, SCHOTT AG, has its headquarters in Mainz (Germany) and is solely owned by the Carl Zeiss Foundation. As a foundation company, SCHOTT assumes special responsibility for its employees, society and the environment.

600450 SCHOTT to Produce More Pharmaceutical Glass
Date: 1 October 2015

See more news about:

See more from these topics:

Others also read

The 14th Otto Schott Research Award recognizes three researchers for their diverse findings on the strength of glass.
The 14th Otto Schott Research Award honors three researchers from three continents for their groundbreaking findings on the strength of glass
Since early researchers first became aware of their potentially deadly effects, the only confirmed form of protection available to those who were required to work with X-rays, gamma rays and similar emissions, was to conceal themselves behind lead sheeting or concrete walls.
SCHOTT PYRANOVA® integrity and insulation fire-resistant glass is being stocked for the first time at SCHOTT UK in Stafford.
SCHOTT’s glass wafers and substrates are transforming radio frequency components and micro-electromechanical systems. Advanced materials from SCHOTT, the international technology group and specialty glass experts, are shaking up the electronics industry.
New multimedia platform highlights innovations made possible with glass - SCHOTT, the international technology group, has launched an online platform that showcases the innovative potential of glass.

Add new comment